Blue Trust Inc. Trims Stake in Eli Lilly and Company

The institutional investor reduced its holdings in the pharmaceutical giant by 5% in Q4 2025.

Apr. 5, 2026 at 7:55am

Got story updates? Submit your updates here. ›

Blue Trust Inc., an institutional investor, trimmed its position in shares of Eli Lilly and Company (NYSE:LLY) by 5.0% during the fourth quarter of 2025, according to the company's latest Form 13F filing with the Securities & Exchange Commission. The investor now owns 85,153 shares of the pharmaceutical company's stock, valued at $91,512,000.

Why it matters

Eli Lilly is one of the world's largest pharmaceutical companies, known for its innovative medicines and therapies. Institutional investors closely monitor their holdings in Lilly, as changes in ownership can signal broader market trends or shifts in investor sentiment around the stock.

The details

In its 13F filing, Blue Trust Inc. reported selling 4,474 shares of Eli Lilly and Company during the fourth quarter. The investor now holds a $91.51 million position in Lilly, accounting for 1.0% of its overall portfolio. Eli Lilly and Company is the 20th largest holding for Blue Trust Inc.

  • Blue Trust Inc. filed its 13F report for the fourth quarter of 2025 on April 5, 2026.

The players

Blue Trust Inc.

An institutional investor that manages a diversified portfolio of stocks, including a $91.51 million position in Eli Lilly and Company.

Eli Lilly and Company

A global pharmaceutical company headquartered in Indianapolis, Indiana, known for its innovative medicines and therapies.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Blue Trust Inc.'s Eli Lilly holdings, while relatively small, could signal broader market trends or shifts in investor sentiment around the pharmaceutical giant. Institutional investors' moves are closely watched for insights into the health of the broader market and individual stocks.